Dolutegravir/lamivudine/tenofovir-disoproxil-fumarate/Efavirenz/lamivudine/tenofovir-disoproxil-fumarateFanconi syndrome

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2013卷 / 1期

关键词：

D O I：

10.1007/s40278-024-61181-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：167 / 167

相关论文

共 50 条

[1] Efavirenz/lamivudine/tenofovir-disoproxil-fumarate/heparinVarious toxicities and lack of efficacy: case report
[J]. Reactions Weekly, 2022, 1914 (1) : 204 - 204
[2] Tenofovir-disoproxil-fumarateFanconi syndrome and osteomalacia
[J]. Reactions Weekly, 2024, 2007 (1) : 317 - 317
[3] Potassium/Tenofovir-disoproxil-fumarateFanconi syndrome and no response
[J]. Reactions Weekly, 2023, 1985 (1) : 439 - 439
[4] Tenofovir-disoproxil-fumarateFanconi syndrome: case report
[J]. Reactions Weekly, 2021, 1850 (1) : 276 - 276
[5] Tenofovir-disoproxil-fumarateFanconi syndrome: case report
[J]. Reactions Weekly, 2022, 1888 (1) : 319 - 319
[6] Tenofovir-disoproxil-fumarateFanconi syndrome: case report
[J]. Reactions Weekly, 2023, 1979 (1) : 443 - 443
[7] Dolutegravir/lamivudine/tenofovir/efavirenz/lamivudine/tenofovirInadvertent administration of dolutegravir/lamivudine/tenofovir, resistance to dolutegravir/lamivudine/tenofovir and efavirenz/lamivudine/tenofovir : case report
[J]. Reactions Weekly, 2019, 1734 (1) : 187 - 187
[8] Dolutegravir plus lamivudine plus tenofovir disoproxil fumarate - addition - EML
[J]. SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 138 - 143
[9] Efavirenz/lamivudine/tenofovir-disoproxil-fumarateHypothyroidism
[J]. Reactions Weekly, 2024, 2005 (1) : 345 - 345
[10] Emtricitabine/tenofovir-disoproxil-fumarateFanconi syndrome: case report
[J]. Reactions Weekly, 2022, 1912 (1) : 207 - 207

← 1 2 3 4 5 →